<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602261</url>
  </required_header>
  <id_info>
    <org_study_id>CTAP101-CL-2010</org_study_id>
    <nct_id>NCT03602261</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI</brief_title>
  <official_title>A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy,
      Pharmacokinetics and Pharmacodynamics of CTAP101 (calcifediol) Extended-Release Capsules to
      Treat Secondary Hyperparathyroidism in Subjects with Vitamin D Insufficiency and Chronic
      Kidney Disease Requiring Regular Hemodialysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">February 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mean plasma intact parathyroid hormone (iPTH)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change of at least 30% from pre-treatment baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Treatment-Emergent Adverse Events as assessed by CTCAE version 5.0</measure>
    <time_frame>32 weeks</time_frame>
    <description>Detailed information collected for each TEAE will include: AE number, a description of the event, start date, end date or ongoing as of date, outcome, therapy for event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>74 weeks</time_frame>
    <description>Maximum serum concentration of Calcifediol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase mean serum total 25-hydroxyvitamin D</measure>
    <time_frame>26 weeks</time_frame>
    <description>Increase to ≥30 ng/mL</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Secondary Hyperparathyroidism Due to Renal Causes</condition>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Stage 5 Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 300mcg/weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 300mcg/weekly for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 600mcg/weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 600mcg/weekly for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsules weekly</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Capsules/weekly for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcifediol Oral Capsule</intervention_name>
    <description>Capsule, weekly</description>
    <arm_group_label>CTAP101 Capsules 300mcg/weekly</arm_group_label>
    <arm_group_label>CTAP101 Capsules 600mcg/weekly</arm_group_label>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly</arm_group_label>
    <other_name>CTAP101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Capsule, weekly</description>
    <arm_group_label>Placebo Capsules weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each subject must meet the following criteria to be enrolled into the two cohorts of this
        study:

          1. Be at least 18 years of age.

          2. Be diagnosed with CKD requiring in-center HD tiw for the preceding 6 months, as
             confirmed by medical history.

          3. Be without any disease state or physical condition that might impair evaluation of
             safety or which, in the investigator's opinion, would interfere with study
             participation, including:

               1. Serum albumin ≤ 3.0 g/dL; and,

               2. Serum transaminase (alanine transaminase [ALT], glutamic pyruvic transaminase
                  [SGPT], aspartate aminotransferase [AST] or glutamic oxaloacetic transaminase
                  [SGOT]) &gt; 2.5 times the upper limit of normal at screening.

          4. Be receiving calcimimetic therapy (either etelcalcetide or cinacalcet) and/or
             calcitriol or other 1α-hydroxylated vitamin D analog (paricalcitol or doxercalciferol)
             for at least 1 month at the time of screening for enrollment. At least 50% of enrolled
             subjects will have been receiving calcimimetic therapy.

          5. Exhibit during the initial screening visit:

               1. Plasma iPTH ≥150 pg/mL and &lt;600 pg/mL if receiving etelcalcetide, cinacalcet,
                  calcitriol or other 1α-hydroxylated vitamin D analog (paricalcitol or
                  doxercalciferol); or

               2. Plasma iPTH ≥300 pg/mL and &lt;900 pg/mL if not receiving etelcalcetide, cinacalcet,
                  calcitriol or other 1α-hydroxylated vitamin D analog; and,

               3. Serum total 25-hydroxyvitamin D &lt;30 ng/mL if not receiving vitamin D
                  supplementation.

          6. When otherwise confirmed eligible at Visit 1, must forgo any further treatment with
             etelcalcetide and cinacalcet for the duration of the study and undergo an 8-week
             washout period.

          7. When otherwise confirmed eligible at Visit 1, must forgo any further treatment with
             calcitriol or other 1α-hydroxylated vitamin D analogs or vitamin D supplements for the
             duration of the study and undergo an 8-week washout period.

          8. Exhibit after the 8-week washout period (if required due to prior use of
             etelcalcetide, cinacalcet, calcitriol or other 1α-hydroxylated vitamin D analogs, or
             vitamin D supplementation):

             Cohort 1:

               1. Plasma iPTH increased by at least 50%; and,

               2. Plasma iPTH ≥300 pg/mL and &lt;1,200 pg/mL; or,

             Cohort 2:

             a. Plasma iPTH ≥300 pg/mL and &lt;1,200 pg/mL (approximately half of the subjects will be
             enrolled in each of these two iPTH strata: ≥300 to &lt;600 and ≥600 to &lt;1,200 pg/mL); and

             Cohorts 1 and 2:

               1. Corrected serum calcium &lt;9.8 mg/dL;

               2. Serum total 25-hydroxyvitamin D &lt;30 ng/mL; and,

               3. Serum phosphorus &lt;6.5 mg/dL.

          9. When otherwise confirmed eligible at Visit 1, if taking more than 1,000 mg per day of
             elemental calcium, reduce calcium use (to ≤1,000 mg per day) and/or use non-calcium
             based phosphate binder therapies (as needed) for the duration of the study.

         10. When otherwise confirmed eligible at Visit 1, if taking bone metabolism therapies that
             may interfere with study endpoints, must discontinue use of these agents for the
             duration of the study.

         11. Willing and able to comply with study instructions and commit to all clinic visits for
             the duration of the study.

         12. Female subjects of childbearing potential must be neither pregnant nor lactating and
             must have a negative serum beta-human chorionic gonadotropin (b-hCG) pregnancy test at
             the first screening visit and at other scheduled times.

         13. All female subjects of childbearing potential and male subjects with female partners
             of childbearing potential must agree to use effective contraception (eg, implants,
             injectables, combined oral contraceptives, intrauterine device, sexual abstinence,
             vasectomy or vasectomized partner) for the duration of the study.

         14. Be able to read, understand and sign the subject Informed Consent Form (ICF) or have a
             legal representative sign the ICF.

        4.3 Exclusion Criteria

        Subjects who meet any of the following criteria will be excluded from the study:

          1. Scheduled kidney transplant or parathyroidectomy.

          2. History (prior 2 months) of corrected serum calcium ≥9.8 mg/dL or serum phosphorus

             ≥6.5 mg/dL if not receiving calcitriol or other 1α-hydroxylated vitamin D analog.

          3. Receipt of bisphosphonate therapy or other bone modifying treatment (eg, denosumab)
             within 6 months prior to enrollment.

          4. Known previous or concomitant serious illness or medical condition, such as
             malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic
             disease, intestinal malabsorption disorder, hepatitis or cardiovascular event that in
             the opinion of the investigator may worsen or reduce life expectancy, and/or interfere
             with participation in the study.

          5. History of neurological/psychiatric disorder, including psychotic disorder or
             dementia, or any reason which, in the opinion of the investigator makes adherence to a
             treatment or follow-up schedule unlikely.

          6. Known or suspected hypersensitivity to any of the constituents of the study drugs.

          7. Currently participating in, or has participated in, an interventional/investigational
             study within 30 days prior to study screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luis R Paredes</last_name>
    <phone>13055754167</phone>
    <email>lparedes@opko.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evelyn Cheng</last_name>
    <phone>13055754129</phone>
    <email>echeng@opko.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AKDHC Medical Research Services</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcie Sears</last_name>
      <phone>623-974-1763</phone>
      <email>msears@akdhc.com</email>
    </contact>
    <investigator>
      <last_name>Suzan Buxton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Services</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciria Luevano</last_name>
      <phone>623-780-1371</phone>
      <phone_ext>3720</phone_ext>
      <email>cluevano@akdhc.com</email>
    </contact>
    <investigator>
      <last_name>Sungchun Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Services</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Diaz</last_name>
      <phone>619-461-3894</phone>
      <email>ediaz@akdhc.com</email>
    </contact>
    <investigator>
      <last_name>Nilda R. Neyra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Services</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciria Luevano</last_name>
      <phone>623-780-1371</phone>
      <phone_ext>3720</phone_ext>
      <email>cluevano@akdhc.com</email>
    </contact>
    <investigator>
      <last_name>Romanita Nica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WCCT Global, Inc.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacienda Dialysis Center</name>
      <address>
        <city>Hacienda Heights</city>
        <state>California</state>
        <zip>91745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research CKD/Dialysis &amp; Transplant Division</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Hernandez</last_name>
      <phone>619-461-3894</phone>
    </contact>
    <investigator>
      <last_name>George Fadda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Beach Quest Dialysis Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ontario Dialysis Center</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Garcia</last_name>
      <phone>626-587-9624</phone>
    </contact>
    <investigator>
      <last_name>Abid Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North America Research Institute, Inc.</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Nguyen</last_name>
      <phone>800-797-1695</phone>
    </contact>
    <investigator>
      <last_name>Aamir Jamal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laurel Canyon Dialysis, LLC</name>
      <address>
        <city>Sun Valley</city>
        <state>California</state>
        <zip>91352</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Leonte</last_name>
      <phone>661-753-3654</phone>
    </contact>
    <investigator>
      <last_name>Omaran Abdeen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Farmer, RN</last_name>
      <phone>303-724-7790</phone>
      <email>Beverly.Farmer@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Michel Chonchol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research by Design, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60643</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Ross</last_name>
      <phone>708-952-3040</phone>
    </contact>
    <investigator>
      <last_name>Paul Crawford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northshore University Health</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Stanton</last_name>
      <phone>224-364-7242</phone>
    </contact>
    <investigator>
      <last_name>Stuart Sprague, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renal and Transplant Associates of New England</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Whitbeck</last_name>
      <phone>413-731-1008</phone>
      <phone_ext>700</phone_ext>
      <email>jwhitbeck@rtane.org</email>
    </contact>
    <investigator>
      <last_name>Michael Germain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwest MS Nephrology</name>
      <address>
        <city>McComb</city>
        <state>Mississippi</state>
        <zip>39601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Haydel, RN</last_name>
      <phone>601-684-6380</phone>
      <email>mhaydel@southwmn.com</email>
    </contact>
    <investigator>
      <last_name>Paul Dykes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwest Houston Research LTD</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Chidolue</last_name>
      <phone>281-598-2210</phone>
      <phone_ext>107</phone_ext>
      <email>darlene.chidolue@swhresearch.com</email>
    </contact>
    <investigator>
      <last_name>Marializa Bernardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kidney &amp; Hypertension Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reynaldo Sosa</last_name>
      <phone>210-277-1418</phone>
    </contact>
    <investigator>
      <last_name>Srinath Tamirisa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

